Search - tctmd.com

Displaying 1 - 4 of 4

Sort: Relevancy | Date

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

News Conference News VIVA 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

September 11, 2017

NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin

News Conference News ISC 2017

NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin

March 01, 2017

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.